Triage administration of sucrose for gastroenteritis in children; a randomized controlled trial
Abstract
OBJECTIVES
Gastroenteritis is a common reason for pediatric emergency department (ED) visits. Fasting-induced ketosis has been proposed as a contributing factor that may exacerbate vomiting. We evaluated whether administration of a concentrated sucrose solution improves oral intake.
METHODS
We conducted a double-blind randomized controlled trial in a tertiary pediatric ED (2022-2024). Children aged 6 months to 7 years with vomiting most likely due to gastroenteritis were enrolled. Participants received a single dose of either sucrose solution (1.5 mL/kg, 3.5 g of sucrose/10 mL), or diluted juice alone (0.5 g of sucrose/10 mL), followed by oral rehydration therapy. The primary outcome was the volume of rehydration solution ingested (mL) within the first 2 h. Secondary outcomes included vomiting episodes, ondansetron use, return visits, and intravenous rehydration.
RESULTS
Of 2001 children screened, 240 (12.0%) were eligible and enrolled; 208 (92%) had primary outcome data. Participants were randomized to the sucrose group (n = 111) or the placebo group (n = 116). There was no significant difference in the volume of rehydration solution ingested between groups (84 mL vs 95 mL; mean difference - 11 mL; 95% CI -26 to 4). There were also no significant differences in the mean number of vomiting episodes (0.46 vs 0.47), intravenous rehydration (14% vs 12%), return visits (5% vs 4%) or ondansetron use (70% vs 68%).
CONCLUSION
A single dose of sucrose solution does not improve oral…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 116 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.